{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Interferon+gamma-1b+%28%22Actimmune%22%29&page=2",
    "query": {
      "intervention": "Interferon gamma-1b (\"Actimmune\")",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 113,
    "total_pages": 12,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Interferon+gamma-1b+%28%22Actimmune%22%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Interferon+gamma-1b+%28%22Actimmune%22%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T00:08:45.468Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02948426",
      "title": "Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Autologous Monocytes + ACTIMMUNE + SYLATRON",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 18,
      "start_date": "2017-02-08",
      "completion_date": "2020-09-29",
      "has_results": true,
      "last_update_posted_date": "2026-01-08",
      "last_synced_at": "2026-10-11T00:08:45.468Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02948426"
    },
    {
      "nct_id": "NCT06909110",
      "title": "Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adenovirus",
        "Cytomegalovirus Infections",
        "Epstein-Barr Virus Infections"
      ],
      "interventions": [
        {
          "name": "Adenovirus Specific T- Lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cytomegalovirus Specific T-Lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Epstein-Barr Virus Specific T-Lymphocytes",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Jessie L. Alexander",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "1 Month to 65 Years"
      },
      "enrollment_count": 25,
      "start_date": "2025-04-30",
      "completion_date": "2032-01-01",
      "has_results": false,
      "last_update_posted_date": "2025-08-14",
      "last_synced_at": "2026-10-11T00:08:45.468Z",
      "location_count": 3,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06909110"
    },
    {
      "nct_id": "NCT05463133",
      "title": "Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Granulomatous Disease"
      ],
      "interventions": [
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Pheripheral blood stem cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Emapalumab-Izsg",
          "type": "DRUG"
        },
        {
          "name": "Tociluzumab",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "4 Years to 65 Years"
      },
      "enrollment_count": 50,
      "start_date": "2022-07-08",
      "completion_date": "2032-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-11T00:08:45.468Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05463133"
    },
    {
      "nct_id": "NCT02143518",
      "title": "Safety and Immunogenicity Study of Na-GST-1 With or Without CpG",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hookworm Infection",
        "Hookworm Disease"
      ],
      "interventions": [
        {
          "name": "Na-GST-1/Alhydrogel®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CpG 10104",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 24,
      "start_date": "2014-10",
      "completion_date": "2016-10",
      "has_results": true,
      "last_update_posted_date": "2025-07-04",
      "last_synced_at": "2026-10-11T00:08:45.468Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02143518"
    },
    {
      "nct_id": "NCT00043316",
      "title": "Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "interferon gamma-1b",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "InterMune",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2001-02",
      "completion_date": "2002-10",
      "has_results": false,
      "last_update_posted_date": "2007-11-01",
      "last_synced_at": "2026-10-11T00:08:45.468Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00043316"
    },
    {
      "nct_id": "NCT03985423",
      "title": "A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Hemophagocytic Lymphohistiocytoses"
      ],
      "interventions": [
        {
          "name": "Emapalumab-Lzsg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Swedish Orphan Biovitrum",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2020-06-02",
      "completion_date": "2021-06-29",
      "has_results": true,
      "last_update_posted_date": "2023-10-06",
      "last_synced_at": "2026-10-11T00:08:45.468Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03985423"
    },
    {
      "nct_id": "NCT00000857",
      "title": "A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Interleukin-12",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 65,
      "start_date": null,
      "completion_date": "2001-06",
      "has_results": false,
      "last_update_posted_date": "2021-10-29",
      "last_synced_at": "2026-10-11T00:08:45.468Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000857"
    },
    {
      "nct_id": "NCT00753467",
      "title": "A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "IFN-γ 1b (Actimmune)",
          "type": "DRUG"
        },
        {
          "name": "Adefovir dipivoxil",
          "type": "DRUG"
        },
        {
          "name": "IFN-γ 1b and Adefovir dipivoxil combination",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Huntington Medical Research Institutes",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 30,
      "start_date": "2008-09",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2010-10-21",
      "last_synced_at": "2026-10-11T00:08:45.468Z",
      "location_count": 1,
      "location_summary": "Pasadena, California",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00753467"
    },
    {
      "nct_id": "NCT00002475",
      "title": "Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Colorectal Cancer",
        "Kidney Cancer",
        "Lung Cancer",
        "Malignant Mesothelioma",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "allogeneic tumor cell vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "autologous tumor cell vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant interferon gamma",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "St. Vincent Medical Center - Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "1991-04",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2013-07-10",
      "last_synced_at": "2026-10-11T00:08:45.468Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002475"
    },
    {
      "nct_id": "NCT04048018",
      "title": "Performance Evaluation of the VIDAS TB-IGRA Assay.",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Active Tuberculosis",
        "Latent Tuberculosis Infection",
        "Non-Tuberculous Mycobacterial (NTM) Pneumonia"
      ],
      "interventions": [
        {
          "name": "Blood draw and IGRA test",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "BioMérieux",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 2401,
      "start_date": "2019-12-05",
      "completion_date": "2021-06-30",
      "has_results": false,
      "last_update_posted_date": "2021-07-16",
      "last_synced_at": "2026-10-11T00:08:45.468Z",
      "location_count": 7,
      "location_summary": "Palo Alto, California • San Diego, California • Denver, Colorado + 4 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04048018"
    }
  ]
}